ArticleFrontiers in oncology2026
Adult-type diffuse glioma prediction using MnasNet optimized by the advanced single candidate optimizer.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Diffuse glioma is the most common and aggressive type of the primary brain tumor of adults that has few treatment options with poor prognosis. Existing diagnostic methods including biopsy and histopathological examination are invasive, time consuming and prone to inter-observer variations. To overcome these shortcomings, this paper suggests a non-invasive, deep learning-based approach to the prediction of adult-type diffuse glioma using preoperative T2-weighted MRI. The paradigm incorporates the alternated MnasNet design which is optimized by a new metaheuristic-based algorithm called the Advanced Single Candidate Optimizer (ASCO) but with the addition of opposition-based learning and Chebyshev chaotic map. The method was trained and tested on a pooled set of 533 patients, 237 of Nagoya University Hospital and 296 of a publicly accessible database coordinated of ground-truth (IDH mutation and 1p/19q codeletion status). Strict 10-fold cross-validation was conducted on an independent test set with a sensitivity of 95.11, specificity of 96.57, precision of 98.75, accuracy of 97.30, F1-score of 97.76 and a Matthews Correlation Coefficient of 92.62. Comparative analyses shows the best result toward six state of the art techniques to prove the clinical potential of the proposed system to predict glioma accurately and non-invasively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.